We are thrilled to announce that Nichepharm Lifesciences Limited have received the prestigious “Supplier Excellence Award” from Procter & Gamble for the year 2023. Out of 70,000 active external business partners, Nichepharm is proud to be among the 80 winners selected. This remarkable achievement is a testament to our unwavering commitment to excellence and the exceptional quality of our products and services.
This award reflects the hard work, dedication, and innovation of our exceptional team at Nichepharm. We're immensely grateful for their commitment to excellence, which has made these achievements possible. As we continue on our journey of excellence, we remain committed to delivering exceptional service and exceeding expectations.
Congratulations to P&G’s 2023 Excellence Award Winners (pgsupplier.com)We are delighted to share that we've been awarded the title of “Strategic Business Partner” by Abbott India. This recognition highlights our contributions during unprecedented times and reinforces our dedication to serving our partners with excellence and integrity. Nichepharm has consistently strived towards achieving the highest standards of quality, at par with international benchmarks and this award further motivates team to raise the bar high.
We extend our sincere gratitude to Abbott India for their trust and partnership. It is through collaborative relationship like this that we're able to make a meaningful impact and drive mutual success.
We are proud to announce that Nichepharm Lifesciences has been listed among the top pharmaceutical contract manufacturers in India by a leading Pharma Magazine. This recognition highlights the company's exceptional growth, and commitment to quality in the highly competitive pharmaceutical manufacturing sector.
In a short span of time, Nichepharm has carved out a name for itself in the contract manufacturing industry. Nichepharm is now one of the leading suppliers of quality injectables, boasting the largest capacity for small volume parenteral production under one roof in India. This rapid rise to prominence underscores the company's commitment to excellence, innovation, and quality in pharmaceutical manufacturing.
https://www.indiapharmaoutlook.com/digital-magazine/pharma-contract-manufacturing-companies-july-2022/#page=10Nichepharm Lifesciences Private Limited, led by the Sobti Family, has acquired the remaining 24% shares from their joint venture partner, Recipharm AB (Sweden), thereby restoring full ownership of the company. This strategic manoeuvre marks a pivotal moment in Nichepharm’s trajectory, empowering the company to steadfastly pursue its vision.
In 2019, Nichepharm, under the stewardship of Dr. Chetan Sobti and Mr. Nitin Sobti, entered into a joint venture with Recipharm. The partnership has fostered substantial growth and fruitful collaboration over the past five years.
Nichepharm remains committed to delivering cutting-edge pharmaceutical solutions while upholding stringent standards of quality to ensure ongoing customer satisfaction. The company is now poised to accelerate its development initiatives, broaden its product portfolio, and explore new opportunities in global markets.
Importantly, Nichepharm assures all stakeholders that this transaction will not impact current operations or the availability of its products. Customers can continue to expect the same exceptional levels of service and product excellence from Nichepharm.
Avendus supported the family with strategic wealth advisory. Khaitan & Co acted as the legal advisors and Dhruva Advisors offered tax advisory services to Nichepharm.